Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Short term Debt (2024 - 2025)

Kura Oncology (KURA) has disclosed Short term Debt for 2 consecutive years, with $4.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Short term Debt rose 152.89% to $4.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.3 million, a 152.89% increase, with the full-year FY2024 number at $2.6 million, changed N/A from a year prior.
  • Short term Debt was $4.3 million for Q3 2025 at Kura Oncology, up from $3.1 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $4.3 million in Q3 2025 to a low of $847000.0 in Q2 2024.